BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG

There is no fulltext present in this item.

Title:	BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG
Author(s):	Kamat, A.M.; Colombel, M.; Sundi, D.; Lamm, D.; Boehle, A.; Brausi, M. ; Buckley, R.; Persad, R.; Palou, J.; Soloway, M.; Witjes, J.A.
Publication year:	2017
Source:	Nature Reviews. Urology, vol. 14, iss. 4, (2017), pp. 244-255
ISSN:	1759-4812
DOI:	https://doi.org/10.1038/nrurol.2017.16
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/174185
Display more details
Subject:	Radboudumc 15: Urological cancers RIMLS: Radboud Institute for Molecular Life Sciences
Organization:	Urology
Journal title:	Nature Reviews. Urology
Volume:	vol. 14
Issue:	iss. 4
Page start:	p. 244
Page end:	p. 255
Abstract:	Intravesical immunotherapy with live attenuated BCG remains the standard of care for patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Most patients initially respond, but recurrence is frequent and progression to invasive cancer is a concern. No established and effective intravesical therapies are available for patients whose tumours recur after BCG, representing a clinically important unmet need. Development and discovery of treatment options for BCG-unresponsive NMIBC is a high priority in order to decrease the morbidity, burden of health-care expenditures, and mortality related to bladder cancer. This Review of treatment options after BCG failure focuses on principles of optimal management emerging therapies, thus enabling a synthesis of recommendations for management for such patients.